231 related articles for article (PubMed ID: 36335368)
1. Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism.
Li YX; Lu YP; Tang D; Hu B; Zhang ZY; Wu HW; Fan LJ; Cai KW; Tang C; Zhang YQ; Hong L; Dong JJ; Guan BZ; Yin LH; Dai Y; Bai WB; Zheng ZH; Zhu T
J Transl Med; 2022 Nov; 20(1):510. PubMed ID: 36335368
[TBL] [Abstract][Full Text] [Related]
2. Cyanidin-3-O-glucoside ameliorates diabetic nephropathy through regulation of glutathione pool.
Qin Y; Zhai Q; Li Y; Cao M; Xu Y; Zhao K; Wang T
Biomed Pharmacother; 2018 Jul; 103():1223-1230. PubMed ID: 29864902
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease.
Yang C; Xiao C; Zhai X; Liu J; Yu M
J Diabetes Complications; 2024 Feb; 38(2):108652. PubMed ID: 38190779
[TBL] [Abstract][Full Text] [Related]
4. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.
Chen DQ; Zhang HJ; Zhang W; Feng K; Liu H; Zhao HL; Li P
Exp Gerontol; 2024 Apr; 188():112393. PubMed ID: 38458480
[TBL] [Abstract][Full Text] [Related]
5. Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis.
Dai Y; Quan J; Xiong L; Luo Y; Yi B
Ren Fail; 2022 Dec; 44(1):862-880. PubMed ID: 35611435
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice.
Wang P; Guo R; Bai X; Cui W; Zhang Y; Li H; Shang J; Zhao Z
Front Endocrinol (Lausanne); 2022; 13():1034818. PubMed ID: 36589853
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.
Lu YP; Zhang ZY; Wu HW; Fang LJ; Hu B; Tang C; Zhang YQ; Yin L; Tang DE; Zheng ZH; Zhu T; Dai Y
J Transl Med; 2022 Sep; 20(1):420. PubMed ID: 36104729
[TBL] [Abstract][Full Text] [Related]
8. Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis".
Han C; Shen Z; Cui T; Ai SS; Gao RR; Liu Y; Sui GY; Hu HZ; Li W
J Ethnopharmacol; 2023 May; 307():116257. PubMed ID: 36787845
[TBL] [Abstract][Full Text] [Related]
9. Clinical metabolomics characteristics of diabetic kidney disease: A meta-analysis of 1875 cases with diabetic kidney disease and 4503 controls.
Yuan Y; Huang L; Yu L; Yan X; Chen S; Bi C; He J; Zhao Y; Yang L; Ning L; Jin H; Yang R; Li Y
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3789. PubMed ID: 38501707
[TBL] [Abstract][Full Text] [Related]
10. Effects of Zhuang medicine compound Xiancao Granule on diabetic kidney disease: A multi-omics analysis.
Mo C; Zhao J; Liang J; Chen Y; Wang H; Dai Y; Huang G
J Ethnopharmacol; 2024 Mar; 321():117517. PubMed ID: 38042391
[TBL] [Abstract][Full Text] [Related]
11. Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
Zhu H; Bai M; Xie X; Wang J; Weng C; Dai H; Chen J; Han F; Lin W
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014850
[TBL] [Abstract][Full Text] [Related]
12. Serum metabolomics detected by LDI-TOF-MS can be used to distinguish between diabetic patients with and without diabetic kidney disease.
Qian F; Zhao L; Zhang D; Yu M; Zhou W; Jin J
FEBS Open Bio; 2023 Oct; 13(10):1844-1858. PubMed ID: 37525631
[TBL] [Abstract][Full Text] [Related]
13. The Qi-Bang-Yi-Shen formula ameliorates renal dysfunction and fibrosis in rats with diabetic kidney disease via regulating PI3K/AKT, ERK and PPARγ signaling pathways.
Wang Z; Jian G; Chen T; Chen Y; Li J; Wang N
Eur J Histochem; 2023 Mar; 67(1):. PubMed ID: 36856315
[TBL] [Abstract][Full Text] [Related]
14. Baicalin ameliorates renal fibrosis by upregulating CPT1α-mediated fatty acid oxidation in diabetic kidney disease.
Hu H; Li W; Hao Y; Peng Z; Zou Z; Liang W
Phytomedicine; 2024 Jan; 122():155162. PubMed ID: 37922789
[TBL] [Abstract][Full Text] [Related]
15. Lipin-1 deficiency deteriorates defect of fatty acid β-oxidation and lipid-related kidney damage in diabetic kidney disease.
Lin S; Wang L; Jia Y; Sun Y; Qiao P; Quan Y; Liu J; Hu H; Yang B; Zhou H
Transl Res; 2024 Apr; 266():1-15. PubMed ID: 37433392
[TBL] [Abstract][Full Text] [Related]
16. A hyaluronan synthesis inhibitor delays the progression of diabetic kidney disease in a mouse experimental model.
Selman G; Martinez L; Lightle A; Aguilar A; Woltmann D; Xiao Y; Vazquez-Padron RI; Salman LH
Kidney360; 2021 May; 2(5):809-818. PubMed ID: 34350420
[TBL] [Abstract][Full Text] [Related]
17. Maresin 1 Alleviates Diabetic Kidney Disease via LGR6-Mediated cAMP-SOD2-ROS Pathway.
Li X; Xu B; Wu J; Pu Y; Wan S; Zeng Y; Wang M; Luo L; Zhang F; Jiang Z; Xu Y
Oxid Med Cell Longev; 2022; 2022():7177889. PubMed ID: 35498124
[TBL] [Abstract][Full Text] [Related]
18. Key enzyme in charge of ketone reabsorption of renal tubular SMCT1 may be a new target in diabetic kidney disease.
Guo Z; Zhong F; Hou M; Xie J; Zhang AZ; Li X; Li Y; Chang B; Yang J
Nephrol Dial Transplant; 2023 Nov; 38(12):2754-2766. PubMed ID: 37698892
[TBL] [Abstract][Full Text] [Related]
19. Artemether Alleviates Diabetic Kidney Disease by Modulating Amino Acid Metabolism.
Rong G; Weng W; Huang J; Chen Y; Yu X; Yuan R; Gu X; Wu X; Cai Y; Han P; Shao M; Sun H; Ge N
Biomed Res Int; 2022; 2022():7339611. PubMed ID: 35601149
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
Hu Y; Tang W; Liu W; Hu Z; Pan C
Drug Des Devel Ther; 2022; 16():1605-1620. PubMed ID: 35669284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
